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IntactParathyroidHormone:Performanceand ClinicalUtilityof an AutomatedAssay
Based on High-PerformanceImmunoaffinityChromatographyand
ChemiluminescenceDetection
David S. Hage,’ Bob Taylor,2 and Pal C. Kao2
The performance and clinical utility of an automated
assay of intact parathyroid hormone (parathyrin, PTH) are
evaluated. The method is based on the extraction of PTH
from plasma by an HPLC column containing immobilized
anti-(44-68 PTH) antibodies. The PTH retained is de-
tected with a postcolumn reactor and use of anti-(1--34
PTh) chemiluminescent-labeledantibodies. The total cy-
cle time of the assay is 6.5 mm per injection after a 1-h
incubation. The lower limit of detection for PTH in a 66-pL
plasma sample was 0.5 pmol/L based on peak heights
and 0.2 pmol/L based on peak areas. Mean analytical
recovery for PTH added to plasma was 97%. The within-
day precisions (CVs) for 4.2 and 30 pmol/L PTH plasma
samples were 9.2% and 5.6% and the day-to-day preci-
sions were 10.3% and 5.7%, respectively. No significant
interferences from 1-34,44-68, or 53-84 PTH fragments
were noted, even at highly increased concentrations of
fragments. The correlation of results with those of a
manual assay of intact PTH was 0.97, and the results
showed good agreement with disease state for patients
with hypo- or hyperparathyroidism. The specificity of the
assay for primary hyperparathyroldism was >95%. We
discuss the advantages (speed and quality control)of this
approach over current immunoassays and the potential
use of this method for detecting other analytes.
AddItional IC.yphra.es: hype.parathyroldtsm chronic renal
failure - hypercalcemle of malignancy
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The measurement of parathyrin (parathyroid hor-
mone; PTH), an 84-amino-acid peptide produced by the
parathyroid glands, is a useful tool in the diagnosis of
calcium disorders.3 The main function of PTH is to
control the concentration of calcium in extracellular
fluids, with the excretion of PTH increasing as the
calcium concentrations decrease (1,2). Normal concen-
trations of intact PTH in plasma range from -1 to 5
pmol/L, with both the increased and decreased values
being of clinical interest (2, 3). Besides intact PTH,
various fragments representing the N-terminal, mid-
molecule, and C-terminal regions of PTH are also found
in blood. Most of these fragments are formed afte
release of intact PTH into the circulation, but some
also produced within the parathyroid glands (4). Bo
intact PTH and its N-terminal fragment are biologicall
active, with intact PTH being the predominant activ
form under normal conditions (2).
PTH assays are used clinically in the differenti
diagnosis of disorders that produce hypercalcemia o
hypocalcemia (e.g., primary hyperparathyroidism or hy
percalcemia of malignancy) and in monitoring hon
damage in patients with chronic renal failure (1,2). Th
pathology and clinical importance of these disorde
have been previously discussed(1-6).
Numerous methods are available for the clinical mea
surement of PTH in these disorders. These are typicall
based on immunoassays with antibodies directed tow
the N-terminal, midmolecule, or C-terminal regions o
FFH. One factor complicating the use and comparison o
these assays is that they have different degrees o
responseto intact PTH and its circulating fragments (1
2). Several methods for monitoring only intact
were recently reported, based on two-site immunometri
assays (7-9). In these assays two sets of antibodies
used: one set is immobilized onto a solid support an
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used to bind one end of intact PTH, such as its 1-34
N-terminal region; the second set is labeled and used to
identify the presence of PTH by binding to a second
domain, such as the 44-68 midmolecule region. Given
this combination, only intact FF11 will react with both
sets of antibodies and be detected (7-9).
Routine monitoring of intact PTH is best done with a
method that is not only sensitive but also fast and fully
automatable. However, current intact PTH assays are
manual methods that take a long time to perform (i.e.,
typically 24 h). To overcome these problems, we (10)
recently developed an automated system for intact PTH,
based on high-performance immunoaffinity chromatog-
raphy and chemiluminescence detection (HPIAC/CL).
En this method, PT!! plasma samples are first incubated
with acridinium ester-labeled anti-(1-34 PT!!) anti-
bodies. This mixture is then injected onto a column
containing anti-(44-68 F1’H) antibodies immobilized to
a small-particle, silica-based support. The immobilized
antibodies extract from the sample any intact PTH
present, along with its associated labeled antibodies.
After nonretained components and excess labeled anti-
bodies are washed from the column, a low pH buffer is
applied to elute intact P’FH and its associated labeled
antibodies from the column. As these compounds are
eluted, they are combined on-line with an alkaline
peroxide postcolumn reagent; the resulting production
rf light from the acridinium ester label is measured
with a flow-through detector. The column is then regen-
erated, and the next sample is injected (10).
In a previous report we described the design and
eptimization of this system for PT!! determinations
10). Here we examined the performance and utility of
this method in a routine clinical setting we considered
the response, precision, and accuracy of the method and
the effects of potential interferences, such as circulating
PT!! fragments. We also examined how this method
rrelated with manual PTH immunoassays and corn-
ared the results of this technique for patients with
ypo- and hyperparathyroidism with those obtained for
ormal individuals. The potential advantages and lim-
tations of this method in the automation of immunoas-
ys of PT!! and other compounds are discussed.
aterlals and Methods
eagents
The 1-34, 1-44, 44-68, and 56-84 fragments of hu-
PT!! and 1-84 intact human FF11 were obtained
m Peninsula Labs. (Belmont, CA). The cyanogen
romide-activated Sepharose 4B, goat IgG, and bovine
rum albumin (BSA; RIA grade) were from Sigma
hemical Co. (St. Louis, MO). Triton X-100, electropho-
is grade, was from Fisher Scientific (Fair Lawn, NJ).
-(2-Succinimidyloxycarbonylethyl)-phenyl-10-methyl-
cridinium-9-carboxylate fluorosulfonate (i.e., acridin-
ester) was from London Diagnostics (Eden Prairie,
- The Nucleosil Si-1000 (7-pin particle diameter,
00-nm pore size) was obtained from Alltech Associates
eerfleld, IL). The 0.25-in. (6.3-mm) polymeric beads
in the immunochemiluminornetric assay (ICMA)
were from Micrornembranes, Inc. (Newark, NJ). All
solutions were prepared with water from a Milli-Q
Water System (Millipore, Bedford, MA).
Instrumentation
The chrornatographic system was the same as do-
scribed before (10). We used a Hitachi (Tokyo, Japan)
L-6200 ternary pump for mixing and pumping postcol-
umn reagent and two Hitachi L-6000 isocratic pumps
for delivering the application and elution buffers to the
immunoaffiaity column. Samples were injected with a
Hitachi 655A-40 autosampler. Components leaving the
immunoafflnity column in the elution buffer were do-
tected on-line with an 825-CL chemiluminescence detec-
tor (Jasco, Easton, MD). The application and elution
buffers were applied alternately to the immunoaffinity
column through a column-switching system consisting
of a Rheodyne 5701 tandem enrichment valve and a Vici
DVI actuator (Chromtech, Apple Valley, MN), con-
trolled from the L-6200 pump. The data were collected
and processed by a Hitachi D-2500 Chrornatolntegrator.
Procedures
Anti-(1-34 PTH) antiserum was prepared in goats by
using BSA-conjugated 1-44 PT!! as the initial immu-
nogen, followed by later injections of unconjugated 1-44
FF1!. Before use, these antibodies were affinity-purified
in columns containing 1-34 FFH fragments immobi-
lized onto a 7 mm (i.d.) x 15 cm cyanogen bromide-
activated Sepharose 4B column (10).
Anti-(44--68 FFH) antiserum was prepared by inject-
ing goats with BSA-conjugated 44-68 Fr!!. The anti-
(44-68 P’FH) antibodies were also affinity-purified, with
use of 44-68 PTH fragments immobilized onto a 7 mm
(i.d.) x 15 cm cyanogen bromide-activated Sepharose 4B
column (10).
The anti-(1-34 FF11) antibodies were labeled with
acridimum ester and purified on a 7 mm (i.d.) x 15 cm
1-44 PTH cyanogen bromide-activated Sepharose 4B
affinity column as described previously (11). Active
labeled antibodies collected from the affinity column
were diluted in 0.10 mol/L phosphate buffer, pH 7.4,
containing 1 g of BSA, 1 g of goat IgG, and 1 mL of
Triton X-100 per liter, then stored at -20 #{176}Cuntil
required for further use.
The manual ICMA assay used in the correlation
studies was performed as described previously (9). The
acridinium ester-labeled anti-(1-34 PT!!) antibodies
were the same as used with the HPIAC/CL system. The
beads bearing immobilized antibody were prepared by
attaching the affinity-purified anti-(44-68 FF1!) anti-
bodies to the polymeric beads, according to the manu-
facturer’s instructions. At the end of the assay, we
measured the chemiluminescence of the beads by using
a Magic Lite Analyzer (Ciba Corning, Medfleld, MA).
Chromatography
The immunoaffinity column was prepared as do-
scribed previously (10), by using affinity-purified anti-
(44-68 PT!!) antibodies immobilized onto diol-bonded
Nucleosil Si-1000 silica. Using the bicinchoninic acid
protein assay (12), we estimated that 1.4mg of antibod-
ies per gram of silica was immobilized onto the support.
The anti-(44-68 PTH) Nucleosil support was down-
ward slurry-packed at 25 MPa into 4.0 mm (i.d.) x 2.0
cm stainless steel columns from Upchurch (Oak Harbor,
WA). Samples were injected onto the column in 0.10
mol/L potassium phosphate buffer, pH 7.4, containing 1
mL of Triton X-100 and 1 g of BSA per liter. The
retained PTH was eluted with pH 3.0 potassium phos-
phate buffer (0.10 mol/L), containing Triton X-100, 1
mL/L. All chromatography was performed at room tem-
perature.
FF1! standards were prepared by adding 1-84 human
PT!! to EDTA-treated plasma collected from patients
with hypoparathyroidism and having no endogenous
FF1! production. For analysis, we mixed 200 pL of each
plasma sample with 100 pL of a 50-fold dilution of the
acridinium ester-labeled antibodies in phosphate buffer
(0.10 mol/L, pH 7.4) containing 1 mL of Triton X-100, 1
g of BSA, and 1 g of goat IgG per liter. The samples were
then filtered through 0.45-pm pore size ACRO LC13
disposable filters (Gelman Sciences, Ann Arbor, MI) and
incubated in the autosampler tray of the HPLC at room
temperature for at least 1 h. We then injected 100 pL of
sample onto the HPIAC/CL system at a flow rate of 1.0
mLlmin. We used the following event schedule in each
chromatographic analysis: 0.0 mm, switch column to pH
7.4 phosphate buffer and allow column to regenerate;
1.0 mm, inject sample and wash nonretained compo-
nents and excess labeled antibody from the column; 3.0
mm, switch to pH 3.0 phosphate elution buffer and
detect the FF11 and associated labeled antibodies; 6.5
mm, begin next cycle.
Retained PT!! and associated labeled antibodies were
detected as they eluted from the column by combining
the column eluent with a postcolumn reagent contain-
ing, per liter, 10 mL of Triton X-100, 0.75 mol of sodium
hydroxide, and 0.43 mmol of hydrogen peroxide. This
reagent was prepared on-line, as described previously
(10), and was applied to the system at a flow-rate of 1.0
mL/min. The post-column reagent and column eluent
were combined by using a standard miring tee from
Upchurch. The mixture was then immediately passed
through the flow cell of the on-line chemilumineacence
detector, and the light produced by the acridinium ester
label was monitored.
Subjects
Normal FF11 samples were obtained by collecting
EDTA-treated plasma from 45 healthy volunteers be-
tween ages 20 and 60 y. These volunteers were labora-
tory technicians and individuals participating in a
study to determine normal values. All normal subjects
had total serum calcium concentrations between 2.13
and 2.50 mmol/L (mean 2.29 mmolJL).
EDTA-treated plasma samples were also obtained
from 46 patients with surgically confirmed primary
hyperparathyroidism. These samples were collected be-
fore removal of the affected parathyroid glands. The
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mean total serum calcium in these patients was 2.8#{128}
mmol/L (range 2.50-3.23). The mean serum creatininc
and inorganic phosphorus concentrations in these pa.
tients were 85 pmol/L (range 44-230) and 0.89 mmol/I
(range 0.58-1.26), respectively.
EDTA-treated plasma samples were collected from 40
patients with chronic renal failure. Their mean tots.]
serum calcium concentration was 2.41 mmol/L (range
1.48-2.90), mean serum creatinine was 710 pmoI/L
(210-1200), and mean inorganic phosphorus was 2.2?
mmol/L (range 1.07-5.78).
EDTA-treated plasma samples were obtained from 3
individuals with hypercalcemia of malignancy. The fol-
lowing types of malignancies were represented: squa-
mous cell carcinoma (n = 8), lymphoma (n = 6), breast
cancer (n = 4), renal cell carcinoma (n = 4), multiple
myeloma (n = 4), prostate cancer (n = 2), sarcoidosis (ii
= 2), and 1 each of small cell carcinoma, islet cell
carcinoma, lung adenocarcinoma, hemangiopericytoma,
dysgermmnoma, ovarian tumor, paraganglioma, and
grade 4 adenocarcinoma with an unknown primary
origin. The mean total serum calcium in these patients
was 3.23 mmol/L (range 2.83-3.95). Their mean serum
creatinine and inorganic phosphorus concentrations
were 130 pmol/L (range 60-410) and 1.01 mmol/L
(range 0.58-1.58), respectively.
Results
Assay Performance
The carryover of the HPIAC/CL system was <0.16%,
as determined by mi’king several alternate injections of
1000 and 0 pmoliL FFH plasma standards. On the basis
of these carryover studies and previous work, we devel-
oped the event schedule given in Materials and Meth.
ods. With this scheme, the total chromatographic tim
was only 6.5 mm per injection, following a 1-h incuba
tion of sample with labeled antibody. Earlier studie
have shown that most (>70%) of the PTH and label
antibodies bind within this incubation time (10); co
quently, even samples that are incubated for >1
before injection present only slight variations in th
final signal produced with this system.
Under the above chromatographic conditions, th
minimum turnaround time per sample was -1 h, in
cluding the time required for sample preparation, incu
bation, injection, and analysis. Given a chroma
graphic time of 6.5 mm per sample, the theoreti
throughput of this system is 220 samples per day.
practice, an average calculated throughput of 180 ± 2
samples per day (n = 19 days) has actually been o
tamed.
Typical chromatograms obtained with the HPIAC/C
system are shown in reference 10. An example of
calibration curve generated with this system is sho
in Figure 1. These results were obtained by injecting
single set of plasma standards onto the system. T
quantify the amount of FFH represented by each
one can use either peak heights or areas. Based o
multiple injections of low-concentration PTH stan
the lower limit of detection at a signal-to-noise ratio of
Pm conan, pmoVL
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PTH conc, pmol/L
Fig. 1. TypIcal calibration curve forPTH onthe HPIAC/CLsystem
basedon peak-height measurements
- -, beet-fit line to the first six data points Inthegraph: y = (0.040 ± 0.0O1)x
+ (0.167 ± 0.011). The inse,t shows an expanded view of the graph Inthe
regionof the four lowest concentration standards
Table 1. AnalytIcal Recovery of Intact PTH on the
HPIAC/CL System
pm concn, L
Erdogsneu. Added PScov.r.da R.covsiy, S
2.5 3.1 5.5 98
2.5 7.3 9.5 97
2.5 19.9 20.8 93
3.4 3.7 6.7 94
3.4 6.8 10.4 102
3.4 10.5 13.6 98
Results shown are for single sample Injections.
was determined as 0.2 pmol/L for peak-area measure-
ments and 0.5 pmol/L for peak-height measurements.
These limits of detection reflect the concentration of
injected FF1! required to produce a signal 2 SD above
the signal produced by the zero standard and agree with
previous data obtained with this system (10).
As shown in Figure 1, the linear range (i.e., the range
of concentrations within ± 5% of the best-fit line)
extended up to 38 pmol/L for the peak-height measure-
ments. For peak-area measurements, the same stan-
dards demonstrated a linear range extending to 44
pmol/L. Thus, the peak-height and peak-area calibra-
tion curves had linear ranges for concentrations cover-
ing 1.8 and 2.3 orders of magnitude, respectively. These
results also agree with earlier work on this system (10)
and are similar to linear ranges seen for manual PTH
assays. The dynamic range (i.e., the range of concentra-
tions producing any detectable change, linear or nonlin-
ear, in the response) extended up to at least 250 pmol/L,
with no apparent hook effect.
Analytical recovery of intact PTH in the HPIAC/CL
system was determined by analyzing normal plasma
samples supplemented with various amounts of exoge-
nous intact PTH. As Table 1 illustrates, all samples
showed a high degree of recovery, with values ranging
from 93% to 102% (mean 97%).
Table 2. ParallelIsm of Intact PTH Results on the
HPIAC/CL System
Coed
DIlutlon Measured for dilution
Undiluted 101.0 101.0
1:2 49.4 98.8
1:4 24.6 98.4
1:8 12.7 102.0
1:16 6.41 102.6
Undiluted 39.2 39.2
1:2 19.1 38.2
1:4 10.6 42.4
1:8 4.74 37.6
1:16 2.51 40.2
a Twopatients’ samples were dilutedwitha 0 pmo[/L PTH plasma
standard.
Parallelism of the HPIAC/CL system was assessed by
measuring intact PTH in a series of dilutions prepared
from plasma samples with above-normal concentrations
of FF1!. The data for all diluted samples showed excel-
lent agreement with the results predicted from the
original sample (Table 2). For the first sample, the
average relative error was only -0.6% (range -2.6% to
+ 1.6%); for the other sample, the average relative error
was +1.0% (range -4.1% to +8.2%).
The within-day precision of the automated FF1! assay
was measured by making 20 sequential injections of
plasma samples with either normal or abnormal concen-
trations of FF1! (4.2 and 30 pmolJL, respectively). The
within-day precisions (CVs) for these samples were ±
9.2% and ± 5.6%, respectively. The day-to-day precision
of the system was determined by injecting the same
samples over the course of 10 d. The day-to-day preci-
sion was ± 10.3% for the normal samples and ± 5.7% for
the abnormal samples. All of these results are similar to
those obtained with equivalent manual FFH immune-
metric assays (7, 8).
The immobilized antibody solid-phase used in this
work was stable for several months when stored at 4#{176}C
in pH 7.0 phosphate buffer. When the support was
placed in a column, typical column lifetimes of 200-250
plasma injections were obtained (mean 230, SD 30, for
three columns). This column life is similar to that seen
for other antibodies immobilized to silica (13-16) and
indicates that the system was sufficiently stable for
performing many analyses of patients’ samples.
As shown previously, little or no change in the activ-
ity of the immobilized antibody was found under the
elution conditions used in the HPIAC/CL system (10).
Measuring the total binding capacity of the immobilized
antibody support over multiple elution cycles had shown
that the total binding capacity of the column for 44-68
FFH decreased by <0.3% with each elution cycle (10).
In this study, we further examined column stability by
comparing a series of five calibration curves obtained
over a series of 143 injections with use of a single
column and a single labeled-antibody preparation. Al-
-J
0
4o
30
!20
ICMA PTH conc, pmol/L
Ag. 2. Correlationof HPIAC/CLwith a manual intact PTH immune-
chemlluminometrlcassay (ICMA). Bestfit line:y = (0.99 ± 0.04)x +
(0.7 ± 0.6), corr.coef. = 0.97, n = 130
10 20 30 40
-J
10:
E
a
C.)
C
0
C)
I
1’
0
S
S
a
--
50
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though some random variation was noted between the
individual calibration curves, linear regression of the
slopes and intercepts indicated no significant change
(<6%) in the curves over the course of this study,
whether based on peak heights or peak areas. From this
we concluded that the stability of the immobilized
antibody was not a mnjor factor in limiting the column
life.
One important factor affecting column life was a
buildup in pressure after a large number of plasma
samples were injected. To reduce this pressure increase,
we implemented several precautions throughout this
study, such as filtering all samples before injection and
placing a precolumn filter in the system to prevent
particulate matter from reaching the immobilized-anti-
body column. Changes in the pressure of the system
during the application and elution steps were also
monitored for quality control. Pressure monitoring was
useful because it indicated when and where pressure
was increasing and what type of corrective action was
needed. Typical sources of pressure increases were the
precolumn ifiter and column. To minimize these in-
creases in routine testing, we replaced the frit in the
precolumn filter after every 100 injections and changed
the column after every 200 injections.
To determine the correlation of the HPIAC/CL system
with a manual intact PTH assay, we used both proce-
dures to analyze a series of 130 patients’ samples in
which intact FF1! concentrations ranged from 0.5 to 42
pmol/L. The best-fit line between the results of the two
assays (Figure 2) had a slope (±2 SD) of 0.99 ± 0.04 and
an intercept of 0.70 ± 0.6 pmol’L; the correlation coef-
ficient was 0.97.
ClinicalUtilityand InterferenceStudies
Figure 3 shows the results obtained with the
HPJ.AC/CL system for single determinations of normal
plasma samples and samples obtained from patients
with primary hyperparathyroidism, chronic renal fail-
ure, or hypercalcemia of malignancy. For the 45 normal
samples tested, the mean concentration of intact PTH
was 2.2 pmol/L; the total range of concentrations ob-
served was 0.6-5.6 pmol/L. Using nonparametric anal-
I I I
Normals KM 1 HPT CRF
Fig.3. Plasma concentrations of intact PThmeasured by HPIAC/CL
In normal individuals and in patients with hypercalcernia of malig-
nancy (HM), primary hyperparathyroidlsm (1 #{176}HPT),orchronic renal
failure(CRF)
ysis and a range of ± 2 SD from the mean, we deter-
mined the normal range for intact FF1! by this method
to be 0.9-5.3 pmol/L. This is consistent with normal
ranges reported for manual intact FF11 assays (3, 7,8).
For the 46 patients tested with primary hyperpara-
thyroidism, FFH concentrations ranged from 5.1 to 41.1
pmol/L (mean 14.6 pmol/L). Results for all samples but
one were above the normal range. This gave the
HPIAC/CL method a specificity for primary hyperpara-
thyroidism of >95%; thus, this technique easily discrim-
inates between normal individuals and patients with
primary hyperparathyroidism.
FFH results for patients with chronic renal failure are
also shown in Figure 3. As reported by others, samples
from these patients exhibit a wide range of PTH concen-
trations (9). In our hands, these concentrations ranged
from 3.5 to 90.0 pmol/L, or from normal values up to
extremely high concentrations.
For patients with hypercalcemia of malignancy, most
samples contained either low or undetectable concentra-
tions of FFH (Figure 3). In more than half of the samples
tested (58%), the measured FFH concentrations were
below the lower limit of detection of the system (<0.2
pmol/L). P’FH values measured in the rems%ining pa-
tients ranged from 0.3 to 1.7 pmol/L. Those samples
with results within the normal range included two
patients with metastatic breast cancer and one with
metastatic renal cell carcinoma. Considering all of the
malignancy samples tested, 92% were at or below the
lower limit of the normal range (0.9 pmol/L) and all
were below the mean of the normal range (2.2 pmol/L).
There was no overlap between the FF1! concentrations
in the patients with hypercalcemia of malignancy and
in those with primary hyperparathyroidism.
To test for potential interferences, we added 1-34,
44-68, or 53-84 FF1! to plasma samples containing 0 or
5 pmol of FFH per liter and injected these onto the
HPIAC/CL system. The concentration of FF1! frag-
ments added to the samples ranged from 0 to 35 nmol/L.
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In these studies, we noted no detectable interference in
either the 0 or 5 pmol/L FF1! samples at concentrations
as great as 30 nmol/L for 53-84 PTH or 20 nmolJL for
44-68 FFH. No interference from 1-34 FF1! was seen
for a fragment concentration as great as 250 pmolfL.
These quantities of fragments exceed the concentrations
seen in most clinical situations, including chronic renal
failure, and indicate that little interference would be
expected from these fragments in routine testing. The
1-34 P’TH results also suggest that this assay would
have little or no interference from PTH-related peptide,
which has its greatest structural homology with FF1! in
the 1-13 N-terminal region (17).
DIscussion
This study demonstrates that HPIAC/CL is a useful
approach to the routine analysis of intact FF1!. Not only
is the method fully automatable, but it also has preci-
sions, limits of detection, and results comparable with
those of current PTH assays. This development is im-
portant because no fully automated method for FF1! has
previously been reported.
One key advantage of this method is that its overall
analysis time (i.e., 1 h per sample) is significantly
shorter than that reported for comparable manual PTH
assays. For example, Nussbaum et al. (8) reported a
24-h immunoradiometric assay for quantifying intact
FF1! in 200 L of serum; its limit of detection was -0.1
pmol/L. Brown et al. (9) reported a 5-h manual ICMA
for 100-zL samples, with a limit of detection of 0.8
pmol/L.
One reason for the greater speed of this method is the
much larger excess of antibody used in the HPIAC/CL
system than is typically present in a manual immunoas-
say support. This allows for more rapid binding between
the immobilized antibody and the FF11-labeled-anti-
body complex. The support used in the HPIAC/CL sys-
tem is also much smaller than that used in manual
immunoassays; this results in faster mass transfer and
also provides for more rapid extraction of the FFH-
labeled-antibody complex. In previous studies (10), we
showed that the combination of these two factors pro-
duced a net rate of extraction of FF1! and its associated
labeled antibody 2400-fold faster than that for the
same sample and antibodies used with a standard im-
munoassay bead.
This HPIAC/CL method is not limited to FF1! but can
be adapted to detect other compoundsby using different
labeled antibodies and columns. Such an approach
should be particularly useful in analyzing other low-
concentration peptide hormones for which automated
systems are not available (e.g., calcitonin and corticotro-
pin). We are also examining the use of HPIAC/CL to
determine smaller molecules.
One potential advantage of HPIAC/CL over existing
methods for P’FH is that it analyzes samples sequentially
rather than in a batch mode. This should make
HPIAC/CL potentially easier for troubleshooting and
maintaining quality control. For example, if the result
for a control sample is outside its allowed limits with
HPIAC/CL, it is relatively easy to change the column or
buffers and recheck the control without wasting a sub-
stantial amount of time before patients’ samples are
tested. In contrast, the long analysis times of manual
FF1! methods means that controls and samples must
be analyzed simultaneously. This creates a problem if the
results for the controls are later found to be outside
acceptable limits, because diagnosing and fixing the
problem may take several days. This increases time and
cost because the patients’ samples must be redetermined.
The fast analysis times of HPIAC/CL make it attrac-
tive to use for rapid determinations of individual sam-
ples or for small-scale routine analysis. For situations
requiring throughput of several hundred samples per
day, either multiple HPIAC/CL systems or batch-mode
manual immunoassays are recommended.
In summary, 1!PIAC/CL is an attractive alternative
to manual methods for determining intact FF1! in
plasma. This method has the advantages of being both
fast and fully automatable, while retaining the accu-
racy, precision, and response of manual P’FH assays. In
addition, HPIAC/CL has the potential of being more
cost-effective and of maintaining quality control more
easily than present batch assays. All of these character-
istics make this approach appealing for use in the
routine monitoring of intact FF1! and other low-concen-
tration analytes.
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